(RTTNews) - SeaStar Medical Holding Corp. (ICU) on Thursday said that critically ill pediatric patients with sepsis-associated acute kidney injury who received QUELIMMUNE (SCD-PED) therapy had significantly higher survival rates than a historical comparison group in the primary a
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.